

FILE 'HOME' ENTERED AT 10:13:35 ON 09 MAR 2006

=> file bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

=> set plurals on

SET COMMAND COMPLETED

=> index bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
92.16	92.37

FULL ESTIMATED COST

(FILE 'HOME' ENTERED AT 10:13:35 ON 09 MAR 2006)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODASE, FEDRIP, ...' ENTERED AT 10:13:46 ON 09 MAR 2006

SET PLURALS ON

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 10:14:02 ON 09 MAR 2006  
SEA CYCLOSPORIN AND CARRIER

```

-----
11  FILE ADISCTI
5   FILE ADISNEWS
2   FILE AGRICOLA
2   FILE ANABSTR
5   FILE BIOENG
143 FILE BIOSIS
41  FILE BIOTECHABS
41  FILE BIOTECHDS
131 FILE BIOTECHNO
2   FILE CABA
420 FILE CAPLUS
1   FILE CEABA-VTB
38  FILE DDFU
78  FILE DGENE
7   FILE DISSABS
80  FILE DRUGU
3   FILE EMBAL
567 FILE EMBASE
47  FILE ESBIODASE
6   FILE GENBANK
500 FILE IFIPAT
13  FILE JICST-EPLUS
32  FILE LIFESCI
793 FILE MEDLINE
1   FILE NTIS
114 FILE PASCAL
3   FILE PHIN
9   FILE PROMT
1   FILE RDISCLOSURE
175 FILE SCISEARCH
302 FILE TOXCENTER
7938 FILE USPATFULL
760 FILE USPAT2
273 FILE WPIDS
1   FILE WPIFV

```

273 FILE WPINDEX  
 1 FILE CASREACT  
 21 FILE DPCI  
 2 FILE ENCOMPPAT  
 1336 FILE EPFULL  
 109 FILE GBFULL  
 40 FILE IMSPATENTS  
 99 FILE INPADOC  
 5 FILE JAPIO  
 5 FILE KOREAPAT  
 43 FILE PATDPAFULL  
 5497 FILE PCTFULL  
 2 FILE RAPRA  
 5 FILE RUSSIAPAT  
 L1 QUE CYCLOSPORIN AND CARRIER  
 -----

FILE 'USPATFULL, PCTFULL, EPFULL, MEDLINE, USPAT2, EMBASE, IFIPAT, CAPLUS, TOXCENTER, WPIDS, SCISEARCH, BIOSIS, BIOTECHNO' ENTERED AT 10:16:15 ON 09 MAR 2006

L2 18835 S L1  
 L3 294247 S DIOIC OR PHTHALIC OR ISOPHTHALIC OR TEREPHTHALIC OR AROMATIC  
 L4 42122 S DIBUTYL SEBACATE OR DIBUTYL PHTHALATE  
 L5 193352 S NON-IONIC SURFACTANT OR NONIONIC SURFACTANT OR POLYOXYETHYLAT  
 L6 51340 S GLYCEROL MONOOLEATE OR SORBITAN MONOOLEATE OR GLYCEROL MONOCA  
 L7 796451 S ANTIOXIDANT OR BHA OR BHT OR ALPHA(1A)TOCOPHEROL

=> s 12 and 13 and 14 and 15 and 16  
 L8 10 L2 AND L3 AND L4 AND L5 AND L6

=> dup rem 18  
 PROCESSING COMPLETED FOR L8  
 L9 8 DUP REM L8 (2 DUPLICATES REMOVED)

=> d bib abs 1-8

L9 ANSWER 1 OF 8 USPATFULL on STN  
 AN 2006:40290 USPATFULL  
 TI Solid \*\*\*carriers\*\*\* for improved delivery of active ingredients in pharmaceutical compositions  
 IN Patel, Mahesh, Salt Lake City, UT, UNITED STATES  
 PI US 2006034937 A1 20060216  
 AI US 2005-196805 A1 20050802 (11)  
 RLI Continuation-in-part of Ser. No. US 2003-428341, filed on 1 May 2003, GRANTED, Pat. No. US 6923988 Continuation of Ser. No. US 2001-800593, filed on 6 Mar 2001, GRANTED, Pat. No. US 6569463 Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363  
 DT Utility  
 FS APPLICATION  
 LREP THORPE NORTH & WESTERN, LLP., 8180 SOUTH 700 EAST, SUITE 200, SANDY, UT, 84070, US  
 CLMN Number of Claims: 18  
 ECL Exemplary Claim: 1-81  
 DRWN 4 Drawing Page(s)  
 LN.CNT 2964  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:133829 USPATFULL

TI Pharmaceutical compositions

IN Patel, Satishchandra P., Livingston, NJ, UNITED STATES

PI US 2004102366 A1 20040527

AI US 2003-632969 A1 20030804 (10)

PRAI GB 2002-18003 20020802

DT Utility

FS APPLICATION

LREP Edward A. Meilman, DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 41st Floor,  
1177 Avenue of the Americas, New York, NY, 10036-2714

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 433

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:

(a) a pharmaceutically effective amount of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A,

(b) a \*\*\*carrier\*\*\* medium which is a dialkyl ester of an aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\*, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\* having from 6 to 20 carbon atoms,

(c) a co- \*\*\*carrier\*\*\* having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and

(d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10.

Examples of the \*\*\*carrier\*\*\* medium are \*\*\*dibutyl\*\*\* \*\*\*sebacate\*\*\* and \*\*\*dibutyl\*\*\* \*\*\*phthalate\*\*\*. Examples of the co- \*\*\*carrier\*\*\* are \*\*\*glycerol\*\*\* \*\*\*monooleate\*\*\*, \*\*\*sorbitan\*\*\* \*\*\*monooleate\*\*\*, \*\*\*glycerol\*\*\* \*\*\*monocaprylate\*\*\*, and \*\*\*sorbitan\*\*\* \*\*\*monolaurate\*\*\*.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 2004012770 PCTFULL ED 20040219 EW 200407

TIEN ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING \*\*\*CYCLOSPORIN\*\*\*

TIFR COMPOSITIONS PHARMACEUTIQUES ORALES CONTENANT DE LA CYCLOSPORINE

IN PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US  
[US, US]PA SMYTH, Gyles, Darren, 57-60 Lincoln's Inn Fields, London WC2A 3LS, GB  
[GB, GB], for SD only;PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US  
[US, US]AG SMITH, Gyles, Darren, Marks & Clerk, 57-60 Lincoln's Inn Fields, London  
WC2A 3LS, GB

LAF English

LA English

DT Patent

PI WO 2004012770 A1 20040212

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN  
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL  
SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC  
NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-GB3278 A 20030731

PRAI GB 2002-0218003.2 20020802

ABEN The application discloses a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure

to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising: (a) a pharmaceutically effective amount of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A, (b) a \*\*\*carrier\*\*\* medium comprising a dialkyl ester of an aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\*, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\* having from 6 to 20 carbon atoms, (c) a co-\*\*\*carrier\*\*\* having a hydrophilic balance (HLB) of from 3 to 6, and (d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the \*\*\*carrier\*\*\* medium are \*\*\*dibutyl\*\*\* \*\*\*sebacate\*\*\* and \*\*\*dibutyl\*\*\* \*\*\*phthalate\*\*\*. Examples of the co-; \*\*\*carrier\*\*\* are \*\*\*glycerol\*\*\* \*\*\*monooleate\*\*\*, \*\*\*sorbitan\*\*\* \*\*\*monooleate\*\*\*, \*\*\*glycerol\*\*\* \*\*\*monocaprylate\*\*\*, and \*\*\*sorbitan\*\*\* \*\*\*monolaurate\*\*\*.

ABFR L'invention concerne une composition pharmaceutique concue pour etre administree par voie orale, sous la forme d'une solution homogene qui, lors d'une exposition a l'eau ou aux fluides du tube digestif, presente une taille particulaire inferieure a 5 microns. Ladite solution comprend : (a) une quantite efficace pharmaceutiquement de cyclosporine, en particulier de la Cyclosporine A ; un milieu de support comprenant un ester dialkyle d'un acide dioique aliphatique ou aromatique, ledit groupe alkyle dudit ester dialkyle comportant 2 a 8 atomes de carbone et ledit acide dioique aliphatique ou aromatique comportant 6 a 20 atomes de carbone ; (c) un co-support presentant un equilibre hydrophile (HLB) compris entre 3 et 6 ; et (d) un surfactant non ionique presentant un equilibre hydrophile lipophile (HLB) superieur a 10. Selon l'invention, ledit support peut etre par exemple du sebacate de dibutyle et du phthalate de dibutyle. Selon l'invention, le co-support peut etre du \*\*\*glycerol\*\*\* \*\*\*monooleate\*\*\*, du \*\*\*sorbitan\*\*\* \*\*\*monooleate\*\*\*, du \*\*\*glycerol\*\*\* \*\*\*monocaprylate\*\*\*, et du \*\*\*sorbitan\*\*\* \*\*\*monolaurate\*\*\*.

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:119528 CAPLUS  
DN 140:169649  
TI Microemulsion concentrate formulations of \*\*\*cyclosporins\*\*\*  
IN Patel, Satishchandra Punambhai  
PA USA  
SO Brit. UK Pat. Appl., 15 pp.  
CODEN: BAXXDU  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2391472	A1	20040211	GB 2002-18003	20020802
	GB 2391472	B2	20041208		
	CA 2494761	AA	20040212	CA 2003-2494761	20030731
	WO 2004012770	A1	20040212	WO 2003-GB3278	20030731
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003260706	A1	20040223	AU 2003-260706	20030731
	EP 1572241	A1	20050914	EP 2003-766444	20030731
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005539002	T2	20051222	JP 2004-525534	20030731
	US 2004102366	A1	20040527	US 2003-632969	20030804
PRAI	GB 2002-18003	A	20020802		
	WO 2003-GB3278	W	20030731		

AB A pharmaceutical compn. suitable for oral administration in the form of a homogeneous soln. which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 .mu.m, the soln. comprising: (a) a pharmaceutically effective amt. of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A, (b) a \*\*\*carrier\*\*\* medium comprising a dialkyl ester of an aliph. or arom. \*\*\*dioic\*\*\* acid, the

alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliph. or arom. \*\*\*dioic\*\*\* acid having from 6 to 20 carbon atoms, (c) a co- \*\*\*carrier\*\*\* having a hydrophilic balance (HLB) of from 3 to 6, and (d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the \*\*\*carrier\*\*\* medium are di-Bu sebacate and di-Bu phthalate. Examples of the co- \*\*\*carrier\*\*\* are \*\*\*glycerol\*\*\* \*\*\*monooleate\*\*\*, \*\*\*sorbitan\*\*\* \*\*\*monooleate\*\*\*, \*\*\*glycerol\*\*\* \*\*\*monocaprylate\*\*\*, and \*\*\*sorbitan\*\*\* \*\*\*monolaurate\*\*\*. The compn. may take the form of a drinking soln. or a hard of soft capsule. A microemulsion for filling gelatin capsule contained \*\*\*cyclosporin\*\*\* A 100, di-Bu sebacate 220, \*\*\*glycerol\*\*\* \*\*\*monooleate\*\*\* 220, polyoxyethylene castor (Cremophore EL) 150, and .alpha.-tocopherol 5 mg.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 USPATFULL on STN DUPLICATE 2  
AN 2003:306064 USPATFULL  
TI Solid \*\*\*carriers\*\*\* for improved delivery of active ingredients in pharmaceutical compositions  
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES  
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
PI US 2003215496 A1 20031120  
US 6923988 B2 20050802  
AI US 2003-428341 A1 20030501 (10)  
RLI Continuation of Ser. No. US 2001-800593, filed on 6 Mar 2001, GRANTED, Pat. No. US 6569463 Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363  
DT Utility  
FS APPLICATION  
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 81  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 3364

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 8 USPATFULL on STN  
AN 2003:257302 USPATFULL  
TI Solid \*\*\*carriers\*\*\* for improved delivery of active ingredients in pharmaceutical compositions  
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES  
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
PI US 2003180352 A1 20030925  
AI US 2002-159601 A1 20020530 (10)  
RLI Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363  
DT Utility  
FS APPLICATION  
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 4625

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for

improved delivery of a wide variety of active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. The compositions of the present invention can be used for improved delivery of active ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 8 USPATFULL on STN  
AN 2003:112567 USPATFULL  
TI Pharmaceutical formulations and systems for improved absorption and multistage release of active agents  
IN Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
Venkateshwaran, Srinivasan, Salt Lake City, UT, UNITED STATES  
Krill, Steven L., Park City, UT, UNITED STATES  
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES  
PI US 2003077297 A1 20030424  
AI US 2002-74687 A1 20020211 (10)  
RLI Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, PENDING Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363  
DT Utility  
FS APPLICATION  
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 145  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 4845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 wt. % to about 80 wt. % of the active agent and the second fraction representing about 20 wt. % to about 95 wt. % of the active agent. One or more additional active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 8 USPAT2 on STN  
AN 2003:92739 USPAT2  
TI Solid \*\*\*carriers\*\*\* for improved delivery of hydrophobic active ingredients in pharmaceutical compositions  
IN Patel, Mahesh V., Salt Lake City, UT, United States  
Chen, Feng-Jing, Salt Lake City, UT, United States  
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)  
PI US 6569463 B2 20030527  
AI US 2001-800593 20010306 (9)  
RLI Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, now patented, Pat. No. US 6248363  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Spear, James M.  
LREP Reed, Dianne E., Reed & Eberle LLP  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 3198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid \*\*\*carrier\*\*\*, the solid \*\*\*carrier\*\*\* being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 12 and 13 and 14 and 15 and 17 and co-carrier

10 FILES SEARCHED...

L11 4 L2 AND L3 AND L4 AND L5 AND L7 AND CO-CARRIER

=> d bib abs 1-4

L11 ANSWER 1 OF 4 USPATFULL on STN

AN 2004:133829 USPATFULL

TI Pharmaceutical compositions

IN Patel, Satishchandra P., Livingston, NJ, UNITED STATES

PI US 2004102366 A1 20040527

AI US 2003-632969 A1 20030804 (10)

PRAI GB 2002-18003 20020802

DT Utility

FS APPLICATION

LREP Edward A. Meilman, DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 41st Floor, 1177 Avenue of the Americas, New York, NY, 10036-2714

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 433

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:

(a) a pharmaceutically effective amount of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A,

(b) a \*\*\*carrier\*\*\* medium which is a dialkyl ester of an aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\*, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\* having from 6 to 20 carbon atoms,

(c) a \*\*\*co\*\*\* - \*\*\*carrier\*\*\* having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and

(d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10.

Examples of the \*\*\*carrier\*\*\* medium are \*\*\*dibutyl\*\*\* \*\*\*sebacate\*\*\* and \*\*\*dibutyl\*\*\* \*\*\*phthalate\*\*\*. Examples of the \*\*\*co\*\*\* - \*\*\*carrier\*\*\* are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 2004012770 PCTFULL ED 20040219 EW 200407

TIEN ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING \*\*\*CYCLOSPORIN\*\*\*

TIFR COMPOSITIONS PHARMACEUTIQUES ORALES CONTENANT DE LA CYCLOSPORINE

IN PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US  
[US, US]  
PA SMYTH, Gyles, Darren, 57-60 Lincoln's Inn Fields, London WC2A 3LS, GB  
[GB, GB], for SD only;  
PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US  
[US, US]  
AG SMITH, Gyles, Darren, Marks & Clerk, 57-60 Lincoln's Inn Fields, London  
WC2A 3LS, GB  
LAF English  
LA English  
DT Patent  
PI WO 2004012770 A1 20040212  
DS W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN  
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL  
SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW  
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM  
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC  
NL PT RO SE SI SK TR  
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-GB3278 A 20030731  
PRAI GB 2002-0218003.2 20020802  
ABEN

The application discloses a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising: (a) a pharmaceutically effective amount of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A, (b) a \*\*\*carrier\*\*\* medium comprising a dialkyl ester of an aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\*, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\* having from 6 to 20 carbon atoms, (c) a \*\*\*co\*\*\* - \*\*\*carrier\*\*\* having a hydrophilic balance (HLB) of from 3 to 6, and (d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the \*\*\*carrier\*\*\* medium are \*\*\*dibutyl\*\*\* \*\*\*sebacate\*\*\* and \*\*\*dibutyl\*\*\* \*\*\*phthalate\*\*\*. Examples of the co&shy; \*\*\*carrier\*\*\* are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.

ABFR L'invention concerne une composition pharmaceutique concue pour etre administree par voie orale, sous la forme d'une solution homogene qui, lors d'une exposition a l'eau ou aux fluides du tube digestif, presente une taille particulaire inferieure a 5 microns. Ladite solution comprend : (a) une quantite efficace pharmaceutiquement de cyclosporine, en particulier de la Cyclosporine A ; un milieu de support comprenant un ester dialkyle d'un acide dioique aliphatique ou aromatique, ledit groupe alkyle dudit ester dialkyle comportant 2 a 8 atomes de carbone et ledit acide dioique aliphatique ou aromatique comportant 6 a 20 atomes de carbone ; (c) un co-support presentant un equilibre hydrophile (HLB) compris entre 3 et 6 ; et (d) un surfactant non ionique presentant un equilibre hydrophile lipophile (HLB) superieur a 10. Selon l'invention, ledit support peut etre par exemple du sebacate de dibutyle et du phtalate de dibutyle. Selon l'invention, le co-support peut etre du glycerol monooleate, du sorbitan monooleate, du glycerol monocaprylate, et du sorbitan monolaurate.

L11 ANSWER 3 OF 4 IFIPAT COPYRIGHT 2006 IFI on STN

AN 10595144 IFIPAT;IFIUDB;IFICDB  
TI PHARMACEUTICAL COMPOSITIONS; A HOMOGENEOUS \*\*\*CYCLOSPORIN\*\*\* SOLUTION COMPRISING A \*\*\*CARRIER\*\*\* DIALKYL ESTER OF ALIPHATIC OR \*\*\*AROMATIC\*\*\* \*\*\*DIOIC\*\*\* \*\*\*ACID\*\*\*, HYDROPHILIC LIPOPHILIC BALANCE, FORMING EMULSIONS IN STOMACH WITH GASTROINTESTINAL FLUIDS  
INF Patel; Satishchandra P., Livingston, NJ, US  
IN Patel Satishchandra P  
PAF Unassigned  
PA Unassigned Or Assigned To Individual (68000)  
AG Edward A. Meilman;DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 41st Floor, 1177 Avenue of the Americas, New York, NY, 10036-2714, US  
PI US 2004102366 A1 20040527  
AI US 2003-632969 20030804  
PRAI GB 2002-180032 20020802  
FI US 2004102366 20040527  
DT Utility; Patent Application - First Publication



FS CHEMICAL  
APPLICATION

CLMN 22

AB Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing: (a) a pharmaceutically effective amount of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A, (b) a \*\*\*carrier\*\*\* medium which is a dialkyl ester of an aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\*, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or \*\*\*aromatic\*\*\* \*\*\*dioic\*\*\* \*\*\*acid\*\*\* having from 6 to 20 carbon atoms, (c) a \*\*\*co\*\*\* - \*\*\*carrier\*\*\* having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and (d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the \*\*\*carrier\*\*\* medium are \*\*\*dibutyl\*\*\* \*\*\*sebacate\*\*\* and \*\*\*dibutyl\*\*\* \*\*\*phthalate\*\*\*. Examples of the \*\*\*co\*\*\* - \*\*\*carrier\*\*\* are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.

CLMN 22

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:119528 CAPLUS

DN 140:169649

TI Microemulsion concentrate formulations of \*\*\*cyclosporins\*\*\*

IN Patel, Satishchandra Punambhai

PA USA

SO Brit. UK Pat. Appl., 15 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2391472	A1	20040211	GB 2002-18003	20020802
	GB 2391472	B2	20041208		
	CA 2494761	AA	20040212	CA 2003-2494761	20030731
	WO 2004012770	A1	20040212	WO 2003-GB3278	20030731
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003260706	A1	20040223	AU 2003-260706	20030731
	EP 1572241	A1	20050914	EP 2003-766444	20030731
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005539002	T2	20051222	JP 2004-525534	20030731
	US 2004102366	A1	20040527	US 2003-632969	20030804
PRAI	GB 2002-18003	A	20020802		
	WO 2003-GB3278	W	20030731		

AB A pharmaceutical compn. suitable for oral administration in the form of a homogeneous soln. which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 .mu.m, the soln. comprising: (a) a pharmaceutically effective amt. of a \*\*\*cyclosporin\*\*\*, in particular \*\*\*Cyclosporin\*\*\* A, (b) a \*\*\*carrier\*\*\* medium comprising a dialkyl ester of an aliph. or arom. \*\*\*dioic\*\*\* acid, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliph. or arom. \*\*\*dioic\*\*\* acid having from 6 to 20 carbon atoms, (c) a \*\*\*co\*\*\* - \*\*\*carrier\*\*\* having a hydrophilic balance (HLB) of from 3 to 6, and (d) a \*\*\*non\*\*\* - \*\*\*ionic\*\*\* \*\*\*surfactant\*\*\* having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the \*\*\*carrier\*\*\* medium are di-Bu sebacate and di-Bu phthalate. Examples of the \*\*\*co\*\*\* - \*\*\*carrier\*\*\* are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate. The compn. may take the form of a drinking soln. or a hard of soft capsule. A microemulsion for filling gelatin capsule contained \*\*\*cyclosporin\*\*\* A 100, di-Bu sebacate 220, glycerol monooleate 220, polyoxyethylene castor (Cremophore EL) 150, and .

\*\*\*alpha\*\*\* .- \*\*\*tocopherol\*\*\* 5 mg.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

186.49

281.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.25

-2.25

STN INTERNATIONAL LOGOFF AT 10:30:07 ON 09 MAR 2006